Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Tavalisse Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.02.47

    Tavalisse Coverage for Chronic Immune Thrombocytopenia

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.02.47 alerts

    Get alerted when Policy 05.02.47 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Tavalisse (fostamatinib disodium hexahydrate) for eligible adults with chronic immune thrombocytopenia, subject to plan design, clinical criteria, documentation, and applicable exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyTavalisse Coverage for Chronic Immune Thrombocytopenia
    Policy CodePolicy 05.02.47
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit pretreatment and current platelet counts to initiate prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 weeksInitial authorization period
    3 or 12 monthsContinuation authorization
    <30 x 10^9/LInitial platelet threshold
    2 tablets/dayQuantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Hematologist
    Required specialty
    Not applicableBilling codes

    Coverage Criteria

    Initial Therapy

    When applicable, the member must meet both the Preferred Drug Plan Design and all clinical criteria for initial approval.

    Preferred Drug Plan Design

    • Preferred product failure or intolerance: The member has had an inadequate response to, or an intolerable adverse event with, Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta).
    • Clinical reason to avoid preferred products: The member has a clinical reason to avoid both Alvaiz (eltrombopag choline) and eltrombopag olamine (generic Promacta).
    • Existing covered therapy: The member is currently receiving Tavalisse through insurance, excluding samples and manufacturer patient assistance programs, and is experiencing a positive therapeutic outcome.

    Initial approval for chronic ITP

    • Diagnosis: The member has chronic immune thrombocytopenia (ITP).
    • Prior therapy: The member has had an inadequate response or intolerance to prior therapy such as corticosteroids, immunoglobulins, splenectomy, or thrombopoietin receptor agonists.
    • Platelet and bleeding criteria: The untransfused platelet count at any point before initiation is less than 30 x 10^9/L, OR is 30 x 10^9/L to 50 x 10^9/L with symptomatic bleeding or risk factors for bleeding.<30 x 10^9/L OR 30 x 10^9/L to 50 x 10^9/L with symptomatic bleeding or bleeding risk

      Examples of symptomatic bleeding include significant mucous membrane bleeding, gastrointestinal bleeding, or trauma.

    Continuation Therapy

    Continuation approval is available when one of the following current platelet-count and bleeding-protection pathways is met.

    Continuation therapy

    • Low count without adequate bleeding protection: The current platelet count is less than 50 x 10^9/L, is not sufficient to prevent clinically important bleeding, and the member has not received a maximal Tavalisse dose for at least 8 weeks.<50 x 10^9/L; maximal dose not received for at least 8 weeks

      Authorization may be granted for 3 months.

    • Low count with adequate bleeding protection: The current platelet count is less than 50 x 10^9/L and is sufficient to prevent clinically important bleeding.<50 x 10^9/L

      Authorization may be granted for 12 months.

    • Intermediate platelet count:

    Non-Formulary Exception

    Non-formulary exception coverage requires the approval criteria plus all of the following conditions.

    Non-formulary exception

    • Supported indication: The requested drug is used for an FDA-approved indication or an indication supported by current compendia of literature or accepted guidelines.

      Diagnostic testing or laboratory results are required when applicable.

    • Dose and quantity: The prescribed dose and quantity fall within FDA-approved labeling or dosing guidelines found in current compendia.
    • Formulary alternatives: All covered formulary alternatives on any tier are ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would cause adverse effects.

      Documentation must include chart notes or other documentation showing prior treatment failure, adverse-event severity, prior treatment dosage and duration, or contraindication to formulary alternatives.

    Coverage will not be provided for concomitant use of Tavalisse with other thrombopoietin receptor agonists, including Alvaiz, Promacta, Nplate, Doptelet, or Mulpleta, or with Bruton's tyrosine kinase inhibitors such as Wayrilz.

    Coding and Clinical Thresholds

    Procedures and Billing Codes — Not Applicablemixed
    No codes listed
    Initial platelet count
    Primary thresholdUntransfused platelet count less than 30 x 10^9/L before initiation
    Alternate thresholdPlatelet count of 30 x 10^9/L to 50 x 10^9/L with symptomatic bleeding or risk factors for bleeding
    Symptomatic bleeding examplesSignificant mucous membrane bleeding, gastrointestinal bleeding, or trauma
    Continuation platelet count below 50
    Platelet thresholdCurrent platelet count less than 50 x 10^9/L
    Three-month pathwayCount is insufficient to prevent clinically important bleeding and maximal Tavalisse dosing has not been received for at least 8 weeks

    Provider Requirements and Action Items

    Prior Authorization

    Hematologist Involvement Required

    The medication must be prescribed by or used in consultation with a hematologist.

    Prior Authorization

    Plan Design and Clinical Criteria

    When both requirements apply, the member must meet both the Preferred Drug Plan Design and the criteria for initial approval or continuation of therapy.

    Unsupported block type: prior_auth

    Step Therapy

    Preferred Eltrombopag Pathway

    For initial approval of Tavalisse, document an inadequate response or intolerable adverse event with a preferred eltrombopag product, or a clinical reason to avoid those products. Members already receiving the requested product must be experiencing a positive therapeutic outcome and cannot have obtained it through samples or a manufacturer patient assistance program.

    Clinical Background

    Tavalisse is covered for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Initial and continued authorization consider platelet counts, clinically important bleeding protection, prior treatment response or intolerance, and bleeding risk.

    Definitions and Clinical Terms

    FDA-approved indication
    IndicationTreatment of thrombocytopenia
    PopulationAdult patients with chronic immune thrombocytopenia (ITP)
    Previous treatmentPatients who have had an insufficient response to a previous treatment
    Risk factors for bleeding
    Procedural riskMedical or dental procedure where blood loss is anticipated
    ComorbiditiesPeptic ulcer disease or hypertension
    Treatment-related riskMandated anticoagulation therapy

    Initial Therapy Criteria

    Chronic ITP Initial Approval

    Initial approval requires the applicable Preferred Drug Plan Design and all clinical criteria when both apply.

    Preferred Drug Plan Design

    • Preferred product failure or intolerance: The member has had an inadequate response to, or an intolerable adverse event with, Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta).
    • Clinical reason to avoid preferred products: The member has a clinical reason to avoid both Alvaiz (eltrombopag choline) and eltrombopag olamine (generic Promacta).
    • Existing covered therapy: The member is currently receiving Tavalisse through insurance, excluding samples and manufacturer patient assistance programs, and is experiencing a positive therapeutic outcome.

    Chronic ITP initial approval

    Continuation Criteria

    Chronic ITP Continuation

    Continuation authorization is available when one of the following current platelet-count and bleeding-protection pathways is met.

    Chronic ITP continuation

    • 3-month pathway: The current platelet count is less than 50 x 10^9/L, is insufficient to prevent clinically important bleeding, and maximal Tavalisse dosing has not been received for at least 8 weeks.<50 x 10^9/L

      Authorization may be granted for 3 months.

    • 12-month low-count pathway: The current platelet count is less than 50 x 10^9/L and is sufficient to prevent clinically important bleeding.<50 x 10^9/L

      Authorization may be granted for 12 months.

    Step Therapy Requirements

    StepRequirementPreferred products or exception
    1Before initial Tavalisse approval, meet one applicable pathway.Inadequate response or intolerable adverse event with Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta); a clinical reason to avoid both products; or current Tavalisse treatment through insurance with a positive therapeutic outcome.
    StepRequirementPrior therapy
    2Document inadequate response or intolerance to prior therapy for chronic ITP.Corticosteroids, immunoglobulins, splenectomy, or thrombopoietin receptor agonists.

    Quantity Limits

    Tavalisse quantity limit
    MedicationTavalisse
    Quantity limit2 tablets
    FrequencyPer day
    Tavalisse daily quantity limit
    MedicationTavalisse
    Daily limit2 tablets/day
    Dosage-form limitNo more than 2 tablets in a day
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyTavalisse Coverage for Chronic Immune Thrombocytopenia
    Policy CodePolicy 05.02.47
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit pretreatment and current platelet counts to initiate prior authorization review.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Action ItemsClinical BackgroundDefinitions and Clinical TermsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsQuantity Limits
    The current platelet count is 50 x 10^9/L to 200 x 10^9/L.
    50 x 10^9/L to 200 x 10^9/L

    Authorization may be granted for 12 months.

  1. Elevated platelet count with dose adjustment: The current platelet count is greater than 200 x 10^9/L and less than or equal to 400 x 10^9/L, and Tavalisse dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.>200 x 10^9/L to <=400 x 10^9/L

    Authorization may be granted for 12 months.

  2. Twelve-month pathwayCount is sufficient to prevent clinically important bleeding
    Continuation platelet count intermediate range
    Platelet rangeCurrent platelet count of 50 x 10^9/L to 200 x 10^9/L
    Authorization period12 months
    Clinical basisContinuation authorization is based on the current platelet count and clinical bleeding protection
    Continuation platelet count high range
    Platelet rangeCurrent platelet count greater than 200 x 10^9/L to less than or equal to 400 x 10^9/L
    Dosing requirementTavalisse dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding
    Authorization period12 months
    • Preferred products: Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta).
    • A clinical reason to avoid either preferred product may satisfy this pathway.
    • Current treatment through insurance must be distinguished from treatment obtained through samples or manufacturer assistance.
    Step Therapy

    Prior ITP Therapy Required

    Document inadequate response or intolerance to prior chronic ITP therapy, such as corticosteroids, immunoglobulins, splenectomy, or thrombopoietin receptor agonists.

    • The prior therapy requirement applies to chronic immune thrombocytopenia (ITP) initial approval.
    Documentation Required

    Platelet Count Documentation

    Submit pretreatment and current platelet counts with the prior authorization request.

    • Pretreatment platelet count
    • Current platelet count
    Documentation Required

    Non-Formulary Exception Documentation

    When the requested product is non-formulary, submit documentation showing that the approval criteria and applicable Non-Formulary Exception Criteria are met.

    • Use for an FDA-approved indication or an indication supported by current compendia or accepted guidelines; provide diagnostic testing or laboratory results when applicable.
    • The prescribed dose and quantity must fall within FDA-approved labeling or applicable compendia dosing guidelines.
    • Document that all covered formulary alternatives are ineffective, were ineffective, would be less effective, or would cause adverse effects.
    • Supporting documentation must include chart notes or other records describing prior treatment failure, adverse-event severity when applicable, prior dosage and duration, or contraindication to formulary alternatives.
    Documentation Required

    Clinical Eligibility Documentation

    Document the clinical information supporting eligibility for initial or continuation therapy, including response or intolerance to prior treatment and applicable bleeding risk factors.

    • For initial approval, document chronic ITP and the applicable platelet-count and symptomatic bleeding or bleeding-risk criteria.
    • Examples of bleeding risk factors include an anticipated medical or dental procedure, peptic ulcer disease or hypertension, mandated anticoagulation, and occupation or lifestyle predisposing the member to trauma.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Plan and Formulary Requirements

    Coverage may be denied when applicable plan-design, clinical, preferred-product, or non-formulary requirements are not satisfied. When the product is non-formulary, the Criteria for Approval and the applicable Non-Formulary Exception Criteria must both be met.

    • Meet both the Preferred Drug Plan Design and applicable initial or continuation criteria when both apply.
    • Satisfy the preferred eltrombopag pathway unless a documented clinical reason to avoid the preferred products applies.
    • For non-formulary products, provide required indication, dosing, laboratory, and formulary-alternative documentation.
    Trauma exposureProfession such as construction work or lifestyle such as playing contact sports that predisposes the patient to trauma
    • Diagnosis: The member has chronic immune thrombocytopenia (ITP).
    • Prior therapy: The member has had an inadequate response or intolerance to prior therapy such as corticosteroids, immunoglobulins, splenectomy, or thrombopoietin receptor agonists.
    • Platelet and bleeding criteria: The untransfused platelet count at any point before initiation is less than 30 x 10^9/L, OR is 30 x 10^9/L to 50 x 10^9/L with symptomatic bleeding or risk factors for bleeding.<30 x 10^9/L OR 30 x 10^9/L to 50 x 10^9/L with symptomatic bleeding or bleeding risk

      Examples of symptomatic bleeding include significant mucous membrane bleeding, gastrointestinal bleeding, or trauma.

    12-month intermediate-count pathway: The current platelet count is 50 x 10^9/L to 200 x 10^9/L.50 x 10^9/L to 200 x 10^9/L

    Authorization may be granted for 12 months.

  3. 12-month dose-adjustment pathway: The current platelet count is greater than 200 x 10^9/L to less than or equal to 400 x 10^9/L, and Tavalisse dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.>200 x 10^9/L to <=400 x 10^9/L

    Authorization may be granted for 12 months.